Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2025-07-04 Legal Proceedings Report
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
(補充111/10/17公告)代重要子公司公告遭韓國公平交易委員會 處以罰鍰事宜
Legal Proceedings Report Classification · 95% confidence The document is a regulatory announcement from a listed company (1795 美時) reporting on a legal matter involving a subsidiary and a court decision related to fines imposed by the Korean Fair Trade Commission. It includes details about the event date, involved parties, legal outcomes, and potential financial impact. The document is short (1005 characters) and does not contain financial statements or detailed financial analysis. It is an update on a legal proceeding rather than a full legal report or financial report. Therefore, it fits best under Legal Proceedings Report (LTR).
2025-07-04 Chinese
公告本公司代理發言人異動
Board/Management Information Classification · 100% confidence The document is a short announcement (728 characters) about a change in the company's agent spokesperson, specifying the old and new persons, their titles, and the effective date. It does not contain financial data, report content, or detailed management discussion. It is clearly an announcement of a change in a company's management or key personnel role. Therefore, it fits the category of Board/Management Information (MANG).
2025-06-30 Chinese
公告本公司114年股東常會決議解除董事競業禁止之限制
Board/Management Information Classification · 95% confidence The document is a company announcement regarding a shareholder meeting resolution to lift restrictions on directors engaging in competitive business activities. It includes details about the meeting date, directors involved, and the resolution outcome. The document is short (1184 characters) and focuses on a specific board/management-related decision rather than financial results or reports. There is no indication of financial statements, audit information, or regulatory filings beyond this announcement. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions related to the company's board or senior management.
2025-06-26 Chinese
公告本公司114年股東常會董事補選當選名單
Board/Management Information Classification · 100% confidence The document is a company announcement from a listed company (1795 美時) regarding the election results of a director at the 114th Annual General Meeting (股東常會董事補選當選名單). It details the new director's name, position, shareholding, and effective date. The document is short (1002 characters) and focuses on management changes rather than financial data or full reports. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-06-26 Chinese
公告本公司114年股東常會重要決議事項
AGM Information Classification · 95% confidence The document is a formal announcement from a company (美時) regarding the important resolutions passed at its Annual General Meeting (AGM) held on 114/06/26 (Taiwanese calendar year). It details decisions such as dividend distribution, amendments to the company bylaws, approval of the business report and financial statements for the previous fiscal year, election of a new director, and other matters. The content is focused on the outcomes of the AGM rather than the full report or financial statements themselves. The document length is short (828 characters) and it serves as a summary of AGM resolutions, fitting the category of AGM Information (AGM-R).
2025-06-26 Chinese
本公司董事會通過子公司Lotus International Pte. Ltd.向DUY TAN PHARMACEUTICAL 購買五個產品的越南藥證案
Capital/Financing Update Classification · 95% confidence The document is a disclosure from a listed company (1795 美時) about a board resolution approving a transaction by its subsidiary to purchase product rights from another company. It details the transaction specifics, including dates, amounts, counterparties, and approvals. The document is a regulatory announcement of a corporate transaction rather than a financial report or earnings release. It does not contain financial statements or management discussion but is a formal disclosure of a significant asset acquisition. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including significant asset acquisitions.
2025-06-18 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.